Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1027

1.

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.

Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, El-Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD; DAD study group.

AIDS. 2003 May 23;17(8):1179-93.

PMID:
12819520
2.

Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.

Masiá M, Padilla S, Bernal E, Almenar MV, Molina J, Hernández I, Graells ML, Gutiérrez F.

Clin Ther. 2007 Jul;29(7):1448-55.

PMID:
17825696
3.

Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.

Jones R, Sawleshwarkar S, Michailidis C, Jackson A, Mandalia S, Stebbing J, Bower M, Nelson M, Gazzard BG, Moyle GJ.

HIV Med. 2005 Nov;6(6):396-402.

4.

Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use.

Kwong GP, Ghani AC, Rode RA, Bartley LM, Cowling BJ, da Silva B, Donnelly CA, van Sighem AI, Cameron DW, Danner SA, de Wolf F, Anderson RM.

AIDS. 2006 Oct 3;20(15):1941-50.

PMID:
16988515
5.

Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.

Young J, Weber R, Rickenbach M, Furrer H, Bernasconi E, Hirschel B, Tarr PE, Vernazza P, Battegay M, Bucher HC.

Antivir Ther. 2005;10(5):585-91.

PMID:
16152752
6.

Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.

Rakotoambinina B, Médioni J, Rabian C, Jubault V, Jais JP, Viard JP.

J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):443-9.

PMID:
11511820
7.

Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study.

Brown TT, Li X, Cole SR, Kingsley LA, Palella FJ, Riddler SA, Chmiel JS, Visscher BR, Margolick JB, Dobs AS.

AIDS. 2005 Sep 2;19(13):1375-83.

PMID:
16103768
8.

Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors.

Guaraldi G, Squillace N, Stentarelli C, Orlando G, D'Amico R, Ligabue G, Fiocchi F, Zona S, Loria P, Esposito R, Palella F.

Clin Infect Dis. 2008 Jul 15;47(2):250-7. doi: 10.1086/589294.

PMID:
18532884
9.

Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.

Young J, Rickenbach M, Weber R, Furrer H, Bernasconi E, Hirschel B, Tarr PE, Vernazza P, Battegay M, Bucher HC.

Antivir Ther. 2005;10(1):73-81.

PMID:
15751765
10.

Combination antiretroviral therapy without a nucleoside reverse transcriptase inhibitor: experience from 334 patients in three cohorts.

Calmy A, Petoumenos K, Lewden C, Law M, Bocquentin F, Hesse K, Cooper D, Carr A, Bonnet F; Aquitaine Cohort, Australian HIV Observational Database and St Vincent's Hospital Cohort study groups.

HIV Med. 2007 Apr;8(3):171-80.

11.
12.

Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins.

Rimland D, Guest JL, Hernández I, Del Rio C, Le NA, Brown WV.

HIV Med. 2005 Sep;6(5):326-33.

13.
14.

Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy.

Lainka E, Oezbek S, Falck M, Ndagijimana J, Niehues T.

Pediatrics. 2002 Nov;110(5):e56.

PMID:
12415062
15.
16.
17.

Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001.

Bonnet F, Balestre E, Thiébaut R, Mercié P, Dupon M, Morlat P, Dabis F; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).

HIV Med. 2004 May;5(3):133-9.

18.

Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors.

Galli M, Ridolfo AL, Adorni F, Gervasoni C, Ravasio L, Corsico L, Gianelli E, Piazza M, Vaccarezza M, d'Arminio Monforte A, Moroni M.

J Acquir Immune Defic Syndr. 2002 Jan 1;29(1):21-31.

PMID:
11782586
19.
20.

Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment.

Mauss S, Corzillius M, Wolf E, Schwenk A, Adam A, Jaeger H, Knechten H, Goelz J, Goetzenich A; DAGNA Lipantiretroviral therapy study group.

HIV Med. 2002 Jan;3(1):49-55.

Supplemental Content

Support Center